The immunosuppressant leflunomide appears to be as effective as azathioprine in maintaining remission and delaying disease relapse in people with lupus nephritis, a clinical trial in more than 200 patients in China showed. The study’s results were recently presented at the American College of Rheumatology (ACR) 2018 Annual Meeting in Chicago, detailed…
Nitro-fatty acids — a type of fatty molecule naturally produced in the body — could act as natural inhibitors of the stimulator of IFN genes (STING), a protein involved in inflammatory diseases such as systemic lupus erythematosus (SLE), according to a study. The study, “Nitro-fatty acids are formed in…
One year of treatment with ustekinumab led to sustained reductions in disease activity in systemic lupus erythematosus (SLE) patients, according to a Phase 2 trial. These benefits were also observed in patients who switched from placebo to Janssen‘s therapy at week 24. Trial findings were presented in the study, “…
Corticosteroids and hydroxychloroquine are the most common medications used by patients with systemic lupus erythematosus (SLE) or lupus nephritis (LN), according to a real-world study, which also found very limited use of biologics. The study, “Real World Medication Use in Incident Systemic Lupus Erythematosus and…
Immugenyx, a subsidiary of Hemogenyx Pharmaceuticals, has partnered with Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson Innovation, to develop a new humanized mouse model for systemic lupus erythematosus (SLE). The collaboration was announced by Hemogenyx, a biopharmaceutical company devoted…
DN2 B-cells — a subset of immune B-cells that are rare in healthy individuals, but extremely common in patients with systemic lupus erythematosus (SLE) — play a critical role in the production of harmful autoantibodies and lupus activity, a study reports. Conducted by a team of researchers at the Emory…
Transplanting regulatory T-cells — cells that suppress the immune system — resolved skin inflammation in a patient with systemic lupus erythematosus, Phase 1 clinical trial results show. The study, “Adoptive Regulatory T Cell Therapy in a Patient with Systemic Lupus Erythematosus,” was published in the journal Arthritis &…
Organs affected by autoimmune disease might be able to suppress T-cell function in a manner that is similar to tumors, actively preventing them from causing damage, a study in systemic lupus erythematosus (SLE) shows. The findings, however, suggest that cancer immunotherapies that work to reactivate the immune system could have…
Xencor announced top-line results from its Phase 2 clinical trial testing the candidate antibody therapy XmAb5871 for the treatment of systemic lupus erythematosus (SLE). The antibody seems to help control or reduce lupus disease activity after patients have been…
People with childhood-onset systemic lupus erythematosus (cSLE) develop significant disease-associated damage early in life and have lower quality of life in their adulthood, without achieving medication-free remission, according to a recent Dutch study. The study, “Long‐term clinical outcomes in a cohort of adults with childhood‐onset Systemic Lupus…